FLAMSA-MEL regimen: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of fludarabine, amsacrine, cytarabine (Ara-C)..." |
No edit summary |
||
| Line 9: | Line 9: | ||
==Regimen== | ==Regimen== | ||
{{chemo|FL|Fludarabine}} | |||
{{chemo|AMS|Amsacrine}} | {{chemo|AMS|Amsacrine}} | ||
{{chemo|A|Cytarabine (Ara-C)}} | {{chemo|A|Cytarabine (Ara-C)}} | ||
{{chemo|MEL|Melphalan}} | {{chemo|MEL|Melphalan}} | ||
==Indications== | ==Indications== | ||
*[[Myelodysplastic syndrome]] or secondary [[Acute myeloid leukemia]]<ref name="pmid21963618">{{cite journal| author=Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A et al.| title=Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. | journal=Biol Blood Marrow Transplant | year= 2012 | volume= 18 | issue= 3 | pages= 466-72 | pmid=21963618 | doi=10.1016/j.bbmt.2011.09.006 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21963618 }} </ref> | *[[Myelodysplastic syndrome]] or secondary [[Acute myeloid leukemia]]<ref name="pmid21963618">{{cite journal| author=Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A et al.| title=Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. | journal=Biol Blood Marrow Transplant | year= 2012 | volume= 18 | issue= 3 | pages= 466-72 | pmid=21963618 | doi=10.1016/j.bbmt.2011.09.006 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21963618 }} </ref> | ||
Latest revision as of 18:10, 31 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:
Overview
FLAMSA-MEL regimen refers to a regimen consisting of fludarabine, amsacrine, cytarabine (Ara-C) and melphalan used to upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia.[1]
Regimen
FLFludarabine
AMSAmsacrine
ACytarabine (Ara-C)
MELMelphalan
Indications
- Myelodysplastic syndrome or secondary Acute myeloid leukemia[1]
References
- ↑ 1.0 1.1 Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A; et al. (2012). "Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen". Biol Blood Marrow Transplant. 18 (3): 466–72. doi:10.1016/j.bbmt.2011.09.006. PMID 21963618.